argenx SE (ARGX)

Completion date history

Slipped 7 times — 2842 cumulative days slipped

2029-01-20→2030-07(+527d)
2026-07-31→2030-05(+1370d)
2026-09-18→2026-09-23(+5d)
2027-02→2027-03(+28d)
2026-10-01→2027-10(+365d)
2026-12→2027-06(+182d)
2026-05-15→2027-05-15(+365d)

Timeline — every real change on record

EDGAR5/23/2017, 5:30:00 AM
Filing 8k material
EDGAR6/14/2017, 5:30:00 AM
Filing 8k material
EDGAR6/20/2017, 5:30:00 AM
Filing 8k material
EDGAR7/7/2017, 5:30:00 AM
Filing 8k material
EDGAR8/23/2017, 5:30:00 AM
Filing 8k material
EDGAR8/24/2017, 5:30:00 AM
Filing 8k material
EDGAR9/20/2017, 5:30:00 AM
Filing 8k material
EDGAR9/22/2017, 5:30:00 AM
Filing 8k material
EDGAR9/25/2017, 5:30:00 AM
Filing 8k material
EDGAR9/26/2017, 5:30:00 AM
Filing 8k material
EDGAR10/26/2017, 5:30:00 AM
Filing 8k material
EDGAR10/30/2017, 5:30:00 AM
Filing 8k material
EDGAR11/7/2017, 5:30:00 AM
Filing 8k material
EDGAR12/11/2017, 5:30:00 AM
Filing 8k material
EDGAR3/1/2018, 5:30:00 AM
Filing 8k material
EDGAR3/16/2018, 5:30:00 AM
Filing 8k material
EDGAR3/22/2018, 5:30:00 AM
Filing 8k material
EDGAR3/26/2018, 5:30:00 AM
Filing 8k material
EDGAR4/9/2018, 5:30:00 AM
Filing 8k material
EDGAR4/12/2018, 5:30:00 AM
Filing 8k material
EDGAR4/24/2018, 5:30:00 AM
Filing 8k material
EDGAR5/9/2018, 5:30:00 AM
Filing 8k material
EDGAR6/7/2018, 5:30:00 AM
Filing 8k material
EDGAR6/14/2018, 5:30:00 AM
Filing 8k material
EDGAR6/20/2018, 5:30:00 AM
Filing 8k material
EDGAR6/28/2018, 5:30:00 AM
Filing 8k material
EDGAR7/17/2018, 5:30:00 AM
Filing 8k material
EDGAR7/24/2018, 5:30:00 AM
Filing 8k material
EDGAR8/2/2018, 5:30:00 AM
Filing 8k material
EDGAR8/22/2018, 5:30:00 AM
Filing 8k material
EDGAR8/29/2018, 5:30:00 AM
Filing 8k material
EDGAR9/6/2018, 5:30:00 AM
Filing 8k material
EDGAR9/17/2018, 5:30:00 AM
Filing 8k material
EDGAR9/20/2018, 5:30:00 AM
Filing 8k material
EDGAR10/9/2018, 5:30:00 AM
Filing 8k material
EDGAR10/25/2018, 5:30:00 AM
Filing 8k material
EDGAR11/1/2018, 5:30:00 AM
Filing 8k material
EDGAR12/3/2018, 5:30:00 AM
Filing 8k material
EDGAR12/3/2018, 5:30:00 AM
Filing 8k material
EDGAR1/18/2019, 5:30:00 AM
Filing 8k material
EDGAR2/4/2019, 5:30:00 AM
Filing 8k material
EDGAR2/28/2019, 5:30:00 AM
Filing 8k material
EDGAR3/14/2019, 5:30:00 AM
Filing 8k material
EDGAR3/26/2019, 5:30:00 AM
Filing 8k material
EDGAR5/8/2019, 5:30:00 AM
Filing 8k material
EDGAR5/9/2019, 5:30:00 AM
Filing 8k material
EDGAR5/22/2019, 5:30:00 AM
Filing 8k material
EDGAR5/28/2019, 5:30:00 AM
Filing 8k material
EDGAR8/1/2019, 5:30:00 AM
Filing 8k material
EDGAR10/15/2019, 5:30:00 AM
Filing 8k material
EDGAR10/24/2019, 5:30:00 AM
Filing 8k material
EDGAR11/6/2019, 5:30:00 AM
Filing 8k material
EDGAR11/8/2019, 5:30:00 AM
Filing 8k material
EDGAR12/9/2019, 5:30:00 AM
Filing 8k material
EDGAR1/9/2020, 5:30:00 AM
Filing 8k material
EDGAR1/13/2020, 5:30:00 AM
Filing 8k material
EDGAR2/27/2020, 5:30:00 AM
Filing 8k material
EDGAR3/31/2020, 5:30:00 AM
Filing 8k material
EDGAR5/12/2020, 5:30:00 AM
Filing 8k material
EDGAR5/14/2020, 5:30:00 AM
Filing 8k material
EDGAR5/26/2020, 5:30:00 AM
Filing 8k material
EDGAR5/29/2020, 5:30:00 AM
Filing 8k material
EDGAR7/30/2020, 5:30:00 AM
Filing 8k material
EDGAR7/31/2020, 5:30:00 AM
Filing 8k material
EDGAR10/6/2020, 5:30:00 AM
Filing 8k material
EDGAR10/22/2020, 5:30:00 AM
Filing 8k material
EDGAR11/23/2020, 5:30:00 AM
Filing 8k material
EDGAR1/6/2021, 5:30:00 AM
Filing 8k material
EDGAR1/8/2021, 5:30:00 AM
Filing 8k material
EDGAR2/1/2021, 5:30:00 AM
Filing 8k material
EDGAR2/4/2021, 5:30:00 AM
Filing 8k material
EDGAR3/30/2021, 5:30:00 AM
Filing 8k material
EDGAR5/11/2021, 5:30:00 AM
Filing 8k material
EDGAR5/14/2021, 5:30:00 AM
Filing 8k material
EDGAR6/1/2021, 5:30:00 AM
Filing 8k material
EDGAR6/7/2021, 5:30:00 AM
Filing 8k material
EDGAR7/29/2021, 5:30:00 AM
Filing 8k material
EDGAR12/22/2021, 5:30:00 AM
Filing 8k material
EDGAR1/7/2022, 5:30:00 AM
Filing 8k material
EDGAR1/10/2022, 5:30:00 AM
Filing 8k material
EDGAR1/20/2022, 5:30:00 AM
Filing 8k material
EDGAR3/3/2022, 5:30:00 AM
Filing 8k material
EDGAR3/22/2022, 5:30:00 AM
Filing 8k material
EDGAR3/25/2022, 5:30:00 AM
Filing 8k material
EDGAR5/5/2022, 5:30:00 AM
Filing 8k material
EDGAR5/19/2022, 5:30:00 AM
Filing 8k material
EDGAR6/27/2022, 5:30:00 AM
Filing 8k material
EDGAR7/28/2022, 5:30:00 AM
Filing 8k material
EDGAR8/12/2022, 5:30:00 AM
Filing 8k material
EDGAR9/8/2022, 5:30:00 AM
Filing 8k material
EDGAR9/21/2022, 5:30:00 AM
Filing 8k material
EDGAR10/27/2022, 5:30:00 AM
Filing 8k material
EDGAR11/22/2022, 5:30:00 AM
Filing 8k material
EDGAR11/30/2022, 5:30:00 AM
Filing 8k material
EDGAR12/12/2022, 5:30:00 AM
Filing 8k material
EDGAR1/9/2023, 5:30:00 AM
Filing 8k material
EDGAR1/27/2023, 5:30:00 AM
Filing 8k material
EDGAR1/30/2023, 5:30:00 AM
Filing 8k material
EDGAR3/2/2023, 5:30:00 AM
Filing 8k material
EDGAR3/16/2023, 5:30:00 AM
Filing 8k material
EDGAR4/17/2023, 5:30:00 AM
Filing 8k material
EDGAR4/18/2023, 5:30:00 AM
Filing 8k material
EDGAR5/5/2023, 5:30:00 AM
Filing 8k material
EDGAR5/5/2023, 5:30:00 AM
Filing 8k material
EDGAR6/21/2023, 5:30:00 AM
Filing 8k material
EDGAR6/30/2023, 5:30:00 AM
Filing 8k material
EDGAR7/17/2023, 5:30:00 AM
Filing 8k material
EDGAR7/21/2023, 5:30:00 AM
Filing 8k material
EDGAR7/27/2023, 5:30:00 AM
Filing 8k material
EDGAR9/21/2023, 5:30:00 AM
Filing 8k material
EDGAR10/31/2023, 5:30:00 AM
Filing 8k material
EDGAR11/1/2023, 5:30:00 AM
Filing 8k material
EDGAR11/17/2023, 5:30:00 AM
Filing 8k material
EDGAR11/28/2023, 5:30:00 AM
Filing 8k material
EDGAR12/20/2023, 5:30:00 AM
Filing 8k material
EDGAR1/8/2024, 5:30:00 AM
Filing 8k material
EDGAR1/18/2024, 5:30:00 AM
Filing 8k material
EDGAR2/20/2024, 5:30:00 AM
Filing 8k material
EDGAR2/29/2024, 5:30:00 AM
Filing 8k material
EDGAR3/8/2024, 5:30:00 AM
Filing 8k material
EDGAR3/21/2024, 5:30:00 AM
Filing 8k material
EDGAR3/26/2024, 5:30:00 AM
Filing 8k material
EDGAR3/27/2024, 5:30:00 AM
Filing 8k material
EDGAR3/27/2024, 5:30:00 AM
Filing 8k material
EDGAR4/16/2024, 5:30:00 AM
Filing 8k material
EDGAR5/8/2024, 5:30:00 AM
Filing 8k material
EDGAR5/9/2024, 5:30:00 AM
Filing 8k material
EDGAR6/17/2024, 5:30:00 AM
Filing 8k material
EDGAR6/24/2024, 5:30:00 AM
Filing 8k material
EDGAR6/25/2024, 5:30:00 AM
Filing 8k material
EDGAR7/16/2024, 5:30:00 AM
Filing 8k material
EDGAR7/16/2024, 5:30:00 AM
Filing 8k material
EDGAR7/25/2024, 5:30:00 AM
Filing 8k material
EDGAR9/19/2024, 5:30:00 AM
Filing 8k material
EDGAR10/15/2024, 5:30:00 AM
Filing 8k material
EDGAR10/31/2024, 5:30:00 AM
Filing 8k material
EDGAR11/12/2024, 5:30:00 AM
Filing 8k material
EDGAR11/20/2024, 5:30:00 AM
Filing 8k material
EDGAR12/27/2024, 5:30:00 AM
Filing 8k material
EDGAR1/13/2025, 5:30:00 AM
Filing 8k material
EDGAR2/27/2025, 5:30:00 AM
Filing 8k material
EDGAR3/7/2025, 5:30:00 AM
Filing 8k material
EDGAR3/20/2025, 5:30:00 AM
Filing 8k material
EDGAR4/8/2025, 5:30:00 AM
Filing 8k material
EDGAR4/11/2025, 5:30:00 AM
Filing 8k material
EDGAR4/14/2025, 5:30:00 AM
Filing 8k material
EDGAR4/28/2025, 5:30:00 AM
Filing 8k material
EDGAR5/8/2025, 5:30:00 AM
Filing 8k material
EDGAR5/28/2025, 5:30:00 AM
Filing 8k material
EDGAR6/11/2025, 5:30:00 AM
Filing 8k material
EDGAR6/20/2025, 5:30:00 AM
Filing 8k material
EDGAR6/30/2025, 5:30:00 AM
Filing 8k material
EDGAR7/31/2025, 5:30:00 AM
Filing 8k material
EDGAR8/25/2025, 5:30:00 AM
Filing 8k material
EDGAR10/3/2025, 5:30:00 AM
Filing 8k material
EDGAR10/15/2025, 5:30:00 AM
Filing 8k material
EDGAR10/29/2025, 5:30:00 AM
Filing 8k material
EDGAR10/30/2025, 5:30:00 AM
Filing 8k material
EDGAR11/18/2025, 5:30:00 AM
Filing 8k material
EDGAR12/15/2025, 5:30:00 AM
Filing 8k material
EDGAR1/5/2026, 5:30:00 AM
Filing 8k material
EDGAR1/12/2026, 5:30:00 AM
Filing 8k material
EDGAR1/13/2026, 5:30:00 AM
Filing 8k material
EDGAR2/26/2026, 5:30:00 AM
Filing 8k material
EDGAR2/26/2026, 5:30:00 AM
Filing 8k material
EDGAR3/6/2026, 5:30:00 AM
Filing 8k material
EDGAR3/19/2026, 5:30:00 AM
Filing 8k material
EDGAR3/20/2026, 5:30:00 AM
Filing 8k material
EDGAR4/20/2026, 5:30:00 AM
Filing 8k material
EDGAR5/6/2026, 5:30:00 AM
Filing 8k material
EDGAR5/7/2026, 5:30:00 AM
Filing 8k material
EDGAR5/11/2026, 5:30:00 AM
Filing 8k material
EDGAR6/3/2026, 5:30:00 AM
Filing 8k material
EDGAR6/23/2026, 5:30:00 AM
Filing 8k material
EDGAR7/23/2026, 5:30:00 AM
Filing 8k material
EDGAR7/27/2026, 5:30:00 AM
Filing 8k material
EDGAR8/3/2026, 5:30:00 AM
Filing 8k material
EDGAR8/17/2026, 5:30:00 AM
Filing 8k material
EDGAR8/27/2026, 5:30:00 AM
Filing 8k material
CTGOV9/19/2026, 11:27:51 AM
Trial registered
record_exists false → true
CTGOV9/19/2026, 12:20:24 PM
Trial registered
record_exists false → true
CTGOV9/19/2026, 12:24:04 PM
Trial registered
record_exists false → true
CTGOV9/19/2026, 12:24:13 PM
Trial registered
record_exists false → true
CTGOV9/19/2026, 12:31:06 PM
Trial registered
record_exists false → true
CTGOV9/19/2026, 12:32:14 PM
Trial registered
record_exists false → true
CTGOV9/19/2026, 4:33:54 PM
Trial registered
record_exists false → true
CTGOV9/19/2026, 4:33:54 PM
Trial registered
record_exists false → true
CTGOV9/19/2026, 4:33:55 PM
Trial registered
record_exists false → true
CTGOV9/19/2026, 4:33:55 PM
Trial registered
record_exists false → true
CTGOV9/19/2026, 4:33:56 PM
Trial registered
record_exists false → true
CTGOV9/19/2026, 4:33:56 PM
Trial registered
record_exists false → true
CTGOV9/19/2026, 4:33:57 PM
Trial registered
record_exists false → true
CTGOV9/19/2026, 4:33:57 PM
Trial registered
record_exists false → true
CTGOV9/19/2026, 4:33:58 PM
Trial registered
record_exists false → true
CTGOV9/19/2026, 4:34:06 PM
Trial registered
record_exists false → true
CTGOV9/19/2026, 4:34:06 PM
Trial registered
record_exists false → true
CTGOV9/19/2026, 4:34:07 PM
Trial registered
record_exists false → true
CTGOV9/19/2026, 4:34:07 PM
Trial registered
record_exists false → true
CTGOV9/19/2026, 4:34:08 PM
Trial registered
record_exists false → true
CTGOV9/19/2026, 4:34:08 PM
Trial registered
record_exists false → true
CTGOV9/19/2026, 4:34:09 PM
Trial registered
record_exists false → true
CTGOV9/19/2026, 4:34:09 PM
Trial registered
record_exists false → true
CTGOV9/19/2026, 4:34:10 PM
Trial registered
record_exists false → true
CTGOV9/19/2026, 4:34:10 PM
Trial registered
record_exists false → true
CTGOV9/19/2026, 4:34:12 PM
Trial registered
record_exists false → true
CTGOV9/19/2026, 4:34:13 PM
Trial registered
record_exists false → true
CTGOV9/19/2026, 4:34:13 PM
Trial registered
record_exists false → true
CTGOV9/19/2026, 4:34:14 PM
Trial registered
record_exists false → true
CTGOV9/19/2026, 4:34:14 PM
Trial registered
record_exists false → true
CTGOV9/19/2026, 4:34:15 PM
Trial registered
record_exists false → true
CTGOV9/19/2026, 4:34:15 PM
Trial registered
record_exists false → true
CTGOV9/19/2026, 4:34:16 PM
Trial registered
record_exists false → true
CTGOV9/19/2026, 4:34:16 PM
Trial registered
record_exists false → true
CTGOV9/19/2026, 4:34:17 PM
Trial registered
record_exists false → true
CTGOV9/19/2026, 4:34:24 PM
Trial registered
record_exists false → true
CTGOV9/19/2026, 4:34:25 PM
Trial registered
record_exists false → true
CTGOV9/19/2026, 4:34:25 PM
Trial registered
record_exists false → true
CTGOV9/19/2026, 4:34:26 PM
Trial registered
record_exists false → true
CTGOV9/19/2026, 4:34:26 PM
Trial registered
record_exists false → true
CTGOV9/19/2026, 4:34:27 PM
Trial registered
record_exists false → true
CTGOV9/19/2026, 4:34:27 PM
Trial registered
record_exists false → true
CTGOV9/19/2026, 4:34:28 PM
Trial registered
record_exists false → true
CTGOV9/19/2026, 4:34:28 PM
Trial registered
record_exists false → true
CTGOV9/19/2026, 4:34:29 PM
Trial registered
record_exists false → true
CTGOV9/19/2026, 4:34:34 PM
Trial registered
record_exists false → true
CTGOV9/19/2026, 4:34:35 PM
Trial registered
record_exists false → true
CTGOV9/19/2026, 4:34:35 PM
Trial registered
record_exists false → true
CTGOV9/19/2026, 4:34:36 PM
Trial registered
record_exists false → true
CTGOV9/19/2026, 4:34:37 PM
Trial registered
record_exists false → true
CTGOV9/19/2026, 4:34:37 PM
Trial registered
record_exists false → true
CTGOV9/19/2026, 4:34:38 PM
Trial registered
record_exists false → true
CTGOV9/19/2026, 4:34:38 PM
Trial registered
record_exists false → true
CTGOV9/19/2026, 4:34:39 PM
Trial registered
record_exists false → true
CTGOV9/19/2026, 4:34:39 PM
Trial registered
record_exists false → true
CTGOV9/19/2026, 4:34:44 PM
Trial registered
record_exists false → true
CTGOV9/19/2026, 4:34:44 PM
Trial registered
record_exists false → true
CTGOV9/19/2026, 4:34:45 PM
Trial registered
record_exists false → true
CTGOV9/19/2026, 4:34:45 PM
Trial registered
record_exists false → true
CTGOV9/19/2026, 4:34:46 PM
Trial registered
record_exists false → true
CTGOV9/19/2026, 4:34:46 PM
Trial registered
record_exists false → true
CTGOV9/19/2026, 4:34:47 PM
Trial registered
record_exists false → true
CTGOV9/19/2026, 4:34:47 PM
Trial registered
record_exists false → true
CTGOV9/19/2026, 4:34:48 PM
Trial registered
record_exists false → true
CTGOV9/19/2026, 4:34:48 PM
Trial registered
record_exists false → true
CTGOV9/19/2026, 4:34:57 PM
Trial registered
record_exists false → true
CTGOV9/19/2026, 4:34:57 PM
Trial registered
record_exists false → true
CTGOV9/19/2026, 4:34:58 PM
Trial registered
record_exists false → true
CTGOV9/19/2026, 4:34:58 PM
Trial registered
record_exists false → true
CTGOV9/19/2026, 4:34:59 PM
Trial registered
record_exists false → true
CTGOV9/19/2026, 4:34:59 PM
Trial registered
record_exists false → true
CTGOV9/19/2026, 4:35:00 PM
Trial registered
record_exists false → true
CTGOV9/19/2026, 4:35:00 PM
Trial registered
record_exists false → true
CTGOV9/19/2026, 4:35:01 PM
Trial registered
record_exists false → true
CTGOV9/19/2026, 4:35:01 PM
Trial registered
record_exists false → true
CTGOV9/19/2026, 4:35:03 PM
Trial registered
record_exists false → true
CTGOV9/19/2026, 4:35:03 PM
Trial registered
record_exists false → true
CTGOV9/19/2026, 4:35:04 PM
Trial registered
record_exists false → true
CTGOV9/19/2026, 4:35:07 PM
Trial registered
record_exists false → true
CTGOV9/19/2026, 4:35:08 PM
Trial registered
record_exists false → true
CTGOV9/19/2026, 4:35:08 PM
Trial registered
record_exists false → true
CTGOV9/19/2026, 4:35:09 PM
Trial registered
record_exists false → true
CTGOV9/19/2026, 4:35:09 PM
Trial registered
record_exists false → true
CTGOV9/19/2026, 4:35:10 PM
Trial registered
record_exists false → true
CTGOV9/19/2026, 4:35:10 PM
Trial registered
record_exists false → true
CTGOV9/19/2026, 4:35:12 PM
Trial registered
record_exists false → true
CTGOV9/19/2026, 4:35:13 PM
Trial registered
record_exists false → true
CTGOV9/19/2026, 4:35:13 PM
Trial registered
record_exists false → true
CTGOV9/19/2026, 4:35:14 PM
Trial registered
record_exists false → true
CTGOV9/19/2026, 4:35:14 PM
Trial registered
record_exists false → true
CTGOV9/19/2026, 4:35:15 PM
Trial registered
record_exists false → true
CTGOV9/19/2026, 4:35:15 PM
Trial registered
record_exists false → true
CTGOV9/19/2026, 4:35:16 PM
Trial registered
record_exists false → true
CTGOV9/19/2026, 4:35:16 PM
Trial registered
record_exists false → true
CTGOV9/19/2026, 4:35:17 PM
Trial registered
record_exists false → true
CTGOV9/19/2026, 4:35:25 PM
Trial registered
record_exists false → true
CTGOV9/19/2026, 4:35:26 PM
Trial registered
record_exists false → true
CTGOV9/19/2026, 4:35:26 PM
Trial registered
record_exists false → true
CTGOV9/19/2026, 4:35:27 PM
Trial registered
record_exists false → true
CTGOV9/22/2026, 5:05:31 AM
Trial site count change
location_count 78 → 79
CTGOV9/22/2026, 5:05:31 AM
Trial site count change
location_count 21 → 22
CTGOV9/23/2026, 5:06:01 AM
Trial site count change
location_count 17 → 29
CTGOV9/23/2026, 5:06:07 AM
Trial site count change
location_count 23 → 26
CTGOV9/23/2026, 5:06:08 AM
Trial completion date change
completion_date 2029-05-12 → 2030-07-30
primary_completion_date 2029-01-20 → 2030-07
CTGOV9/23/2026, 5:06:08 AM
Trial status change
overall_status Recruiting → Not yet recruiting
CTGOV9/23/2026, 5:06:09 AM
Trial site count change
location_count 95 → 101
CTGOV9/23/2026, 5:07:01 AM
Trial site count change
location_count 21 → 22
CTGOV9/24/2026, 5:05:46 AM
Trial site count change
location_count 3 → 4
CTGOV9/24/2026, 5:05:47 AM
Trial site count change
location_count 82 → 85
CTGOV9/24/2026, 5:05:49 AM
Trial site count change
location_count 3 → 4
CTGOV9/24/2026, 5:06:40 AM
Trial site count change
location_count 35 → 36
CTGOV9/24/2026, 5:06:45 AM
Trial site count change
location_count 32 → 33
CTGOV9/26/2026, 5:08:06 AM
Trial site count change
location_count 32 → 33
CTGOV9/26/2026, 5:08:07 AM
Trial completion date change
completion_date 2026-07-31 → 2030-05

CTGOV9/26/2026, 5:08:08 AM

Trial endpoint change

secondary_outcomes

[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

→

CTGOV9/26/2026, 5:08:08 AM

Trial eligibility change

eligibility_criteria

Inclusion Criteria: * At least 18 years old * Clinically diagnosed with Guillain-Barré syndrome (GBS) according to NINDS (National Institute of Neurological Disorders and Stroke) diagnostic criteria * GBS-related weakness beginning within 7 days before the first study treatment * GBS Disability Scale (GBS-DS) score of 3, 4, or 5 at screening and baseline * Was able to walk approximately 10 m or more without assistance before the onset of GBS symptoms * Agrees to receive antibiotic prophylaxis against N. meningitidis and S. pneumoniae for the first 90 days of the study or until a completed vaccination schedule against these bacterial pathogens per local guidelines has been shown. Exclusion Criteria: * History of a previous GBS episode or diagnosis of an atypical GBS variant * Clinical diagnosis of systemic lupus erythematosus (SLE) or known complement deficiency * Autoimmune or neuromuscular diseases or medical conditions (eg, clinically significant renal, hepatic, cardiac, pulmonary, hematologic, or neurological conditions or clinically significant laboratory abnormalities) that would interfere with an accurate assessment of clinical symptoms of GBS, confound the study results, or put the participant at undue risk * IVIg therapy contraindications or another medical condition that, in the opinion of the investigator, would make IVIg administration unsafe * Recent treatment with IVIg or plasma exchange (PLEX), or recent use of certain immune-modulating or immunosuppressive therapies

→

Inclusion Criteria: * Clinically diagnosed with Guillain-Barré syndrome (GBS) according to NINDS (National Institute of Neurological Disorders and Stroke) diagnostic criteria * GBS-related weakness beginning within 7 days before the first study treatment * GBS Disability Scale (GBS-DS) score of 3, 4, or 5 at screening and baseline * Was able to walk approximately 10 m or more without assistance before the onset of GBS symptoms * Agrees to receive antibiotic prophylaxis against N. meningitidis and S. pneumoniae for the first 90 days of the study or until a completed vaccination schedule against these bacterial pathogens per local guidelines has been shown. Exclusion Criteria: * History of a previous GBS episode or diagnosis of an atypical GBS variant * Clinical diagnosis of systemic lupus erythematosus (SLE) or known complement deficiency * Autoimmune or neuromuscular diseases or medical conditions (eg, clinically significant renal, hepatic, cardiac, pulmonary, hematologic, or neurological conditions or clinically significant laboratory abnormalities) that would interfere with an accurate assessment of clinical symptoms of GBS, confound the study results, or put the participant at undue risk * IVIg therapy contraindications or another medical condition that, in the opinion of the investigator, would make IVIg administration unsafe * Recent treatment with IVIg or plasma exchange (PLEX), or recent use of certain immune-modulating or immunosuppressive therapies

EDGAR9/29/2026, 5:30:00 AM
Filing 8k material
MARKET10/8/2026, 5:30:00 AM
Unusual volume
EDGAR10/8/2026, 5:30:00 AM
Filing 8k material
MARKET10/8/2026, 5:30:00 AM
Unusual move
CTGOV10/9/2026, 5:07:07 AM
Trial site count change
location_count 23 → 28
CTGOV10/15/2026, 5:06:28 AM
Trial status change
overall_status Recruiting → Completed
CTGOV10/15/2026, 5:06:28 AM
Trial enrollment change
enrollment_type ESTIMATED → ACTUAL
CTGOV10/15/2026, 5:06:28 AM
Trial completion date change
completion_date 2026-09-18 → 2026-09-23
primary_completion_date 2026-09-18 → 2026-09-23
CTGOV10/17/2026, 5:06:18 AM
Trial site count change
location_count 85 → 89
CTGOV10/17/2026, 5:06:18 AM
Trial site count change
location_count 29 → 42
CTGOV10/17/2026, 5:06:19 AM
Trial site count change
location_count 26 → 32
CTGOV10/17/2026, 5:06:20 AM
Trial site count change
location_count 101 → 102
CTGOV10/17/2026, 5:06:55 AM
Trial site count change
location_count 36 → 37
CTGOV10/17/2026, 5:06:58 AM
Trial site count change
location_count 4 → 8
CTGOV10/17/2026, 5:07:06 AM
Trial site count change
location_count 22 → 26
CTGOV10/17/2026, 5:07:30 AM
Trial status change
overall_status Recruiting → Active, not recruiting
CTGOV10/17/2026, 5:07:30 AM
Trial enrollment change
enrollment_type ESTIMATED → ACTUAL
enrollment_count 81 → 87
CTGOV10/17/2026, 5:07:30 AM
Trial completion date change
completion_date 2027-09 → 2027-10
primary_completion_date 2027-02 → 2027-03
CTGOV10/17/2026, 5:07:35 AM
Trial site count change
location_count 4 → 6
EDGAR10/19/2026, 5:30:00 AM
Filing 8k material
CTGOV10/20/2026, 5:05:04 AM
Trial completion date change
completion_date 2026-10-01 → 2027-10
primary_completion_date 2026-10-01 → 2027-10

CTGOV10/20/2026, 5:05:04 AM

Trial endpoint change

primary_outcomes	[object Object],[object Object],[object Object],[object Object]	→	[object Object],[object Object],[object Object],[object Object]
secondary_outcomes	[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]	→	[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

CTGOV10/20/2026, 5:05:04 AM

Trial eligibility change

eligibility_criteria

Inclusion Criteria: 1. Ability to understand the requirements of the trial and provide written informed consent (including consent for the use and disclosure of research-related health information), willing and able to comply with the trial protocol procedures (including attending the required trial visits). 2. Participants enrolled in the ARGX-113-2004 trial who completed the 24-week trial period. Note: If a participant has had an SAE during the ARGX-113-2004 trial, their eligibility should be evaluated by the investigator and the sponsor's trial physician. The decision of enrolling the participant will be evaluated case by case. 3a. Agree to use contraceptives consistent with local regulations and the following: • Female participants of childbearing potential must have a negative urine pregnancy test at baseline before receiving IMP. In addition to the above criteria, for participants who want to continue receiving efgartigimod during an additional 52-week treatment period (only applicable in case efgartigimod is not yet commercially available for patients with primary ITP or available through another patient program for patients with primary ITP), the following criteria apply: 4\. Ability to understand the requirements of the additional 52-week treatment period of the trial, to provide written informed consent (including consent for the use and disclosure of research-related health information), and to comply with the trial protocol procedures (including required trial visits). 5\. Participant has completed a 52-week treatment period. Exclusion criteria: 1. Introduction or continuation of nonpermitted medications during the ARGX-113-2004 trial (such as anti-CD20 therapy, romiplostim, monoclonal antibodies, Fc fusion proteins, or live/live-attenuated vaccines) 2. Use of any other investigational drug or participation in any other investigational trial 3. Known hypersensitivity reaction to efgartigimod PH20 SC or any of its excipients 4. Pregnant or lactating females and those who intend to become pregnant during the trial or within 90 days after last dose of efgartigimod PH20 SC

→

Inclusion Criteria: * Ability to understand the requirements of the trial and provide written informed consent (including consent for the use and disclosure of research-related health information), willing and able to comply with the trial protocol procedures (including attending the required trial visits). * Participants enrolled in the ARGX-113-2004 trial who completed the 24-week trial period. * Agree to use contraceptives consistent with local regulations. * In addition to the above criteria, for participants who want to continue receiving efgartigimod during an additional 52-week treatment period, the participant has completed a 52-week treatment period. Exclusion criteria: * Introduction or continuation of nonpermitted medications during the ARGX-113-2004 trial (such as anti-CD20 therapy, romiplostim, monoclonal antibodies, Fc fusion proteins, or live/live-attenuated vaccines). * Use of any other investigational drug or participation in any other investigational trial. * Known hypersensitivity reaction to efgartigimod PH20 SC or any of its excipients. * Pregnant or lactating females and those who intend to become pregnant during the trial or within 90 days after last dose of efgartigimod PH20 SC.

EDGAR10/22/2026, 5:30:00 AM
Filing 8k material
CTGOV10/28/2026, 5:06:13 AM
Trial status change
overall_status Not yet recruiting → Recruiting
CTGOV10/28/2026, 5:06:13 AM
Trial site count change
location_count 6 → 11

CTGOV10/29/2026, 5:05:15 AM

Trial eligibility change

eligibility_criteria

→

Inclusion Criteria: * Clinically diagnosed with Guillain-Barré syndrome (GBS) according to NINDS (National Institute of Neurological Disorders and Stroke) diagnostic criteria * GBS-related weakness beginning within 7 days before the first study treatment * GBS Disability Scale (GBS-DS) score of 3, 4, or 5 at screening and baseline * Was able to walk approximately 10 m or more without assistance before the onset of GBS symptoms * Agrees to receive antibiotic prophylaxis against N. meningitidis and S. pneumoniae for the first 90 days of the study or until a completed vaccination schedule against these bacterial pathogens per local guidelines has been shown. Exclusion Criteria: * History of a previous GBS episode or diagnosis of an atypical GBS variant * Clinical diagnosis of systemic lupus erythematosus (SLE) or known complement deficiency * Autoimmune or neuromuscular diseases or medical conditions (eg, clinically significant renal, hepatic, cardiac, pulmonary, hematologic, or neurological conditions or clinically significant laboratory abnormalities) that would interfere with an accurate assessment of clinical symptoms of GBS, confound the study results, or put the participant at undue risk * IVIg therapy contraindications or another medical condition that, in the opinion of the investigator, would make IVIg administration unsafe * Recent treatment with IVIg except for a single IVIg dose administered during screening and within 24 hours before the first investigational medicinal product (IMP) dose for the current GBS episode or plasma exchange (PLEX), or recent use of certain immune-modulating or immunosuppressive therapies

CTGOV10/29/2026, 5:05:15 AM
Trial completion date change
completion_date 2027-07 → 2028-06
primary_completion_date 2026-12 → 2027-06
CTGOV10/30/2026, 5:05:36 AM
Trial status change
overall_status Recruiting → Active, not recruiting
CTGOV10/30/2026, 5:05:36 AM
Trial enrollment change
enrollment_type ESTIMATED → ACTUAL
enrollment_count 12 → 15
CTGOV10/31/2026, 5:05:19 AM
Trial site count change
location_count 102 → 103
CTGOV10/31/2026, 5:05:35 AM
Trial completion date change
completion_date 2026-05-15 → 2027-05-15

Relationships — real graph edges

SPONSORS→ Trial_971e31d682eb4fb9836093b529a893f4
SPONSORS→ Trial_7ad57ae1fdc149af84259a90441fa513
SPONSORS→ Trial_2c137cd8353c4f23befc28526f843961
SPONSORS→ Trial_c9159da2aa7b4a3a8227730ded0d8c05
SPONSORS→ Trial_efb8187535db443e8d7e861f367cb2da
SPONSORS→ Trial_c55981b5e3a043ba8047a9376bbcc7fa
SPONSORS→ Trial_a32323f291f1448eb19efc9fcb7e929d
SPONSORS→ Trial_4514650b152f4f5dbb86f1c71b1f91e9
SPONSORS→ Trial_5144861de1c54b9cb09f3bbca1524587
SPONSORS→ Trial_fab27bfd3073478195a128ad4d24f886
SPONSORS→ Trial_be710dbb89944c6c8b58765251e8dee7
SPONSORS→ Trial_1e911bbc2aa74cdf8186e3df1de63d15
SPONSORS→ Trial_5d2f67fcafa845d8a587c9cadc4edbae
SPONSORS→ Trial_d9a53d78571f468cb72e209f8179153e

Evidence — source documents

completion_date	2029-05-12	→	2030-07-30
primary_completion_date	2029-01-20	→	2030-07

completion_date	2026-09-18	→	2026-09-23
primary_completion_date	2026-09-18	→	2026-09-23

completion_date	2027-09	→	2027-10
primary_completion_date	2027-02	→	2027-03

completion_date	2026-10-01	→	2027-10
primary_completion_date	2026-10-01	→	2027-10

completion_date	2027-07	→	2028-06
primary_completion_date	2026-12	→	2027-06